Xiromed intros generic Akovaz

Xiromed, in conjunction with its development partner Aggrega Pharma, is offering ephedrine sulfate injection, 50 mg/ml, which is a generic of Akovaz.   

Ephedrine sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. 

[Read more: Xiromed unveils generic Extina]

Akovaz and its generics had a market value of $49.6 million for the 12-month period ending May, 2023, according to IQVIA.

Rob Spina, CEO of Xiromed said, “I am pleased to announce the launch of ephedrine sulfate injection in partnership with Aggrega Pharma. This launch further bolsters Xiromed’s injectable portfolio and demonstrates our commitment to bringing quality, affordable generic options to the market for U.S. patients.”     

[Read more: Xiromed launches generic Prilosec]

“We are excited to cooperate with Xiromed and launch another Aggrega portfolio product.  Xiromed is a strong partner to make ephedrine sulphate injection a successful product in the U.S. generic market,” said Sergio Simoes, board chair of Aggrega Pharma.